title: Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence.
abstract: The concept of 'niche' has become a focus of attention in hematologic malignancies including acute myeloid leukemia (AML). Similar to normal hematopoietic stem cells, AML cells interact both anatomically and functionally with the stroma within the marrow microenvironment. These interactions have a critical role in the development, progression, and relapse of AML. Chemotherapy resistance is another feature that is at least partially related to AML-stroma interactions. The evidence for safety and efficacy of agents targeting AML-niche interactions is currently limited to preclinical and early phase clinical studies. Examples include CXCR4 inhibitors, hypoxia-inducible agents, and adhesion molecule inhibitors. Agents that target AML-stroma interactions differ from mutation-specific approaches that tend to be limited due to within-individual and between-individual genetic heterogeneity. These agents may be used alone or as chemosensitizers in AML. This novel and rapidly advancing strategy is likely to become an important part of our armamentarium of anti-leukemia treatments in the near future.
authors.affiliation: Section of BMT and Leukemia, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Armin
authors.initials: A
authors.lastname: Rashidi
authors.affiliation: Section of BMT and Leukemia, Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8007, St. Louis, MO 63110, USA.
authors.forename: John F
authors.initials: JF
authors.lastname: DiPersio
keywords: leukemia; microenvironment; niche; stem cell; stroma; therapeutics
references.citation: Blood. 2009 Jun 11;113(24):6206-14
references.pmid: 19050309
references.citation: Blood. 2007 Jan 15;109(2):786-91
references.pmid: 16888090
references.citation: Exp Hematol. 1994 Dec;22(13):1252-60
references.pmid: 7957711
references.citation: Nat Med. 2012 Nov;18(11):1651-7
references.pmid: 23086476
references.citation: Cell. 2006 Jan 27;124(2):407-21
references.pmid: 16439213
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4767-73
references.pmid: 19720922
references.citation: Biophys J. 2001 Aug;81(2):685-96
references.pmid: 11463617
references.citation: Blood. 2012 Apr 26;119(17):3917-24
references.pmid: 22308295
references.citation: Nat Med. 2006 Oct;12(10):1167-74
references.pmid: 16998484
references.citation: Cancer Res. 2014 Jun 1;74(11):3092-103
references.pmid: 24699624
references.citation: Nat Med. 2013 Nov;19(11):1513-7
references.pmid: 24162813
references.citation: Leukemia. 2012 Oct;26(10):2186-96
references.pmid: 22652755
references.citation: Blood. 2004 Jul 15;104(2):550-7
references.pmid: 15054042
references.citation: J Immunol. 2000 Sep 15;165(6):3423-9
references.pmid: 10975862
references.citation: Nature. 2013 Mar 14;495(7440):227-30
references.pmid: 23434756
references.citation: Blood. 2000 Jun 1;95(11):3289-96
references.pmid: 10828007
references.citation: Leukemia. 2014 Oct;28(10 ):1978-87
references.pmid: 24637335
references.citation: Am J Pathol. 2013 Nov;183(5):1608-20
references.pmid: 24160325
references.citation: Nature. 2009 Jan 1;457(7225):97-101
references.pmid: 19052548
references.citation: Clin Cancer Res. 2013 Jan 15;19(2):357-66
references.pmid: 23213054
references.citation: Nat Biotechnol. 2007 Nov;25(11):1315-21
references.pmid: 17952057
references.citation: Leukemia. 2008 Jan;22(1):59-65
references.pmid: 17898789
references.citation: Blood. 2012 Sep 27;120(13):2679-89
references.pmid: 22826565
references.citation: Blood Cells. 1978;4(1-2):7-25
references.pmid: 747780
references.citation: J Cell Biochem. 2014 Jun;115(6):1128-37
references.pmid: 24851270
references.citation: Blood. 2006 Oct 1;108(7):2358-65
references.pmid: 16763210
references.citation: Exp Hematol. 2001 Apr;29(4):448-57
references.pmid: 11301185
references.citation: Nature. 2010 Aug 12;466(7308):829-34
references.pmid: 20703299
references.citation: Cancer Res. 2004 Apr 15;64(8):2817-24
references.pmid: 15087398
references.citation: J Exp Med. 2014 Sep 22;211(10):1925-35
references.pmid: 25180064
references.citation: J Cell Physiol. 2010 Jan;222(1):17-22
references.pmid: 19725055
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5431-6
references.pmid: 17374716
references.citation: Blood. 2002 Sep 15;100(6):2132-7
references.pmid: 12200377
references.citation: Blood. 2009 Jun 11;113(24):6215-24
references.pmid: 18955566
references.citation: Leukemia. 2000 Jul;14(7):1239-46
references.pmid: 10914548
references.citation: Nature. 2013 Mar 14;495(7440):231-5
references.pmid: 23434755
references.citation: Leukemia. 2008 Dec;22(12):2151-5158
references.pmid: 18769446
references.citation: Nat Immunol. 2002 Jul;3(7):687-94
references.pmid: 12068293
references.citation: N Engl J Med. 2012 May 17;366(20):1870-80
references.pmid: 22591293
references.citation: Blood. 1998 Jun 15;91(12):4523-30
references.pmid: 9616148
references.citation: Clin Cancer Res. 2013 Dec 1;19(23):6506-19
references.pmid: 24088735
references.citation: Nat Med. 2013 Jun;19(6):695-703
references.pmid: 23644514
references.citation: Blood. 2011 Sep 8;118(10):2849-56
references.pmid: 21765021
references.citation: Cancer Cell. 2008 Jun;13(6):483-95
references.pmid: 18538732
references.citation: Br J Haematol. 2014 Jan;164(1):61-72
references.pmid: 24116827
references.citation: Nature. 2008 Mar 27;452(7186):442-7
references.pmid: 18256599
references.citation: Immunity. 2006 Dec;25(6):977-88
references.pmid: 17174120
references.citation: Blood. 2012 Jan 12;119(2):540-50
references.pmid: 21957195
references.citation: Immunity. 2010 Sep 24;33(3):387-99
references.pmid: 20850355
references.citation: Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13576-81
references.pmid: 23901108
references.citation: Blood. 2008 Apr 1;111(7):3439-41
references.pmid: 18195093
references.citation: Nature. 2013 Oct 31;502(7473):637-43
references.pmid: 24107994
references.citation: J Clin Oncol. 2011 Feb 10;29(5):591-9
references.pmid: 21220598
references.citation: Cell. 2005 Jul 1;121(7):1109-21
references.pmid: 15989959
references.citation: N Engl J Med. 2013 May 30;368(22):2059-74
references.pmid: 23634996
references.citation: J Clin Invest. 2013 Jun;123(6):2395-407
references.pmid: 23676502
references.citation: Nat Med. 2003 Sep;9(9):1158-65
references.pmid: 12897778
references.citation: Cancer Med. 2014 Apr;3(2):265-72
references.pmid: 24519883
references.citation: Nature. 2010 Apr 8;464(7290):852-7
references.pmid: 20305640
references.citation: Clin Cancer Res. 2010 Jun 1;16(11):2927-31
references.pmid: 20484021
references.citation: J Clin Oncol. 2010 Jun 10;28(17):2831-8
references.pmid: 20421533
references.citation: Nature. 2009 Jan 1;457(7225):92-6
references.pmid: 19052546
references.citation: Stem Cells. 2007 May;25(5):1119-25
references.pmid: 17255519
references.citation: Blood. 2003 Mar 15;101(6):2253-60
references.pmid: 12411310
references.citation: Blood. 2009 Feb 12;113(7):1504-12
references.pmid: 18957686
references.citation: Science. 2008 Dec 19;322(5909):1861-5
references.pmid: 19095944
references.citation: J Biol Chem. 2013 Aug 9;288(32):22899-914
references.pmid: 23798675
references.citation: Blood. 2011 Nov 17;118(20):5583-92
references.pmid: 21948175
references.citation: Blood. 2012 Nov 15;120(20):4205-14
references.pmid: 23012328
references.citation: Exp Hematol. 2007 Feb;35(2):221-9
references.pmid: 17258071
references.citation: Cell Prolif. 2000 Dec;33(6):381-95
references.pmid: 11101010
references.citation: Blood. 2009 Jan 22;113(4):866-74
references.pmid: 18927435
references.citation: Blood. 2009 Jun 4;113(23):5720-6
references.pmid: 19363221
references.citation: Cell Stem Cell. 2014 Sep 4;15(3):365-75
references.pmid: 25017722
references.citation: Blood. 2010 Jul 22;116(3):375-85
references.pmid: 20393133
references.citation: Int J Oncol. 2010 Feb;36(2):415-20
references.pmid: 20043076
references.citation: Cell. 2011 Nov 23;147(5):1146-58
references.pmid: 22118468